Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials
R Panta, K Dahal, S Kunwar - Journal of clinical lipidology, 2015 - Elsevier
Background Low-density lipoprotein cholesterol (LDL-C) is the primary target of lipid-
lowering therapy in people at risk for cardiovascular diseases. Mipomersen inhibits
apolipoprotein B-100 (apoB) synthesis and causes reduction in LDL-C by reducing apoB.
Objective We aimed to perform a meta-analysis of all published randomized controlled trials
comparing safety and efficacy of mipomersen with placebo in adults with dyslipidemia.
Methods We searched PUBMED, CENTRAL, and EMBASE from inception through March …
lowering therapy in people at risk for cardiovascular diseases. Mipomersen inhibits
apolipoprotein B-100 (apoB) synthesis and causes reduction in LDL-C by reducing apoB.
Objective We aimed to perform a meta-analysis of all published randomized controlled trials
comparing safety and efficacy of mipomersen with placebo in adults with dyslipidemia.
Methods We searched PUBMED, CENTRAL, and EMBASE from inception through March …
